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A randomized phase II study of stem cell mobilization
with cyclophosphamide+G-CSF or G-CSF alone after
lenalidomide-based induction in multiple myeloma
R Silvennoinen1, P Anttila2, M Säily3, T Lundan4, J Heiskanen2, TM Siitonen3, S Kakko3, M Putkonen5, H Ollikainen6, V Terävä7, A Kutila8,
K Launonen9, A Räsänen10, A Sikiö11, M Suominen12, P Bazia13, K Kananen13, T Selander14, T Kuittinen1, K Remes5,15 and E Jantunen1
The most common means of mobilizing autologous stem cells is G-CSF alone or combined with cyclophosphamide (CY) to obtain
sufﬁcient CD34+ cells for one to two transplants. There are few prospective, randomized studies investigating mobilization
regimens in multiple myeloma (MM), especially after lenalidomide-based induction. We designed this prospective, randomized
study to compare low-dose CY 2 g/m2+G-CSF (arm A) and G-CSF alone (arm B) after lenalidomide-based up-front induction in MM.
Of the 80 initially randomized patients, 69 patients were evaluable, 34 and 35 patients in arms A and B, respectively. The primary
end point was the proportion of patients achieving a yield of ⩾ 3 × 106/kg CD34+ cells with 1− 2 aphereses, which was achieved in
94% and 77% in arms A and B, respectively (P= 0.084). The median number of aphereses needed to reach the yield of ⩾ 3 × 106/kg
was lower in arm A than in arm B (1 vs 2, P= 0.035). Two patients needed plerixafor in arm A and ﬁve patients in arm B (P= 0.428).
Although CY-based mobilization was more effective, G-CSF alone was successful in a great majority of patients to reach the deﬁned
collection target after three cycles of lenalidomide-based induction.
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INTRODUCTION
Autologous stem cell transplantation (ASCT) as ﬁrst line therapy is
still the backbone in the treatment of younger patients with
multiple myeloma (MM).1–2 There are only few prospective,
randomized trials comparing different mobilization methods in
MM.3–4 Early trials showed some beneﬁt from high (7 g/m2) or
intermediate CY (3− 4 g/m2) compared with low-dose CY
(1.5− 2 g/m2) in terms of total CD34+ cell yields but with increased
toxicity.5–8 It has been assumed that CY would also beneﬁt the
outcome in patients with inferior response before mobilization but
subsequent studies have not conﬁrmed this.7,9 With novel agents,
it is possible to achieve at least a very good partial response for
55− 75% of patients before mobilization.1
Prolonged exposure to lenalidomide may impair the mobilization
of CD34+ cells without impact on engraftment kinetics.10–13 If stem
cell mobilization is scheduled in the early phase (⩽3−4 cycles of
lenalidomide-based induction), the rate of failure to achieve grafts for
1− 2 transplants is diminished.14–15 The possible negative effect of
lenalidomide on successful harvesting could be overcome by adding
CY or plerixafor to G-CSF.16–18 The International Myeloma Working
Group suggested that G-CSF alone would be adequate for initial
mobilization in MM patients aged o65 years with fewer than four
cycles of lenalidomide but encourages prospective trials investigating
the up-front use of plerixafor.19 The American Society for Blood and
Marrow Transplantation has published guidelines for autologous
stem cell mobilization20–21 and recommended early collection
between the second and fourth cycles of lenalidomide whenever
possible.20 The phase III study published by DiPersio et al.22 showed
that G-CSF+plerixafor was superior to G-CSF+placebo in MM in terms
of optimal CD34+ cell yield and the number of apheresis needed. Of
note, only o10% of patients had received lenalidomide before
mobilization in that trial. In a recent paper of Clark et al.,23 the prior
therapies correlated with the risk of mobilization failure in the group
mobilized with chemotherapy plus G-CSF but not in the plerixafor
+G-CSF group. Mohty et al.24 concluded that preemptive intervention
based on the CD34+ cell count prior to apheresis might help to
rescue the mobilization failure.
The present phase II randomized prospective multicenter
mobilization study was designed as a substudy in the Finnish
Myeloma Study Group-MM02 trial to compare the efﬁcacy of
low-dose CY 2 g/m2+G-CSF vs G-CSF alone after lenalidomide,
bortezomib and dexamethasone (RVD) induction. To the best of
our knowledge, this is the ﬁrst prospective randomized trial on
stem cell mobilization after RVD induction.
MATERIALS AND METHODS
Study design
This phase II multicenter trial was conducted at 12 centers in Finland.
Transplant-eligible patients aged ⩽ 70 years with untreated symptomatic
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MM were randomized 1:1 at inclusion into one of the two mobilization
arms. Computer-generated random arms were assigned to patients.
Principal investigator was responsible for inclusion and randomization.
The main exclusion criteria were peripheral neuropathy grade ⩾ 2,
signiﬁcant liver dysfunction, severe cardiac dysfunction, severe renal
failure (glomerular ﬁltration rate o15ml/min, unless in hemodialysis) and
contraindication for the use of thromboprophylaxis or history of active
malignancy during the past 5 years, with the exception of basal cell
carcinoma of the skin or stage 0 cervical carcinoma. The Research Ethics
Committee of the Northern Savo Hospital District approved the study
protocol, and it was conducted according to the Declaration of Helsinki,
International Conference of Harmonization and Guidelines for Good
Clinical Practice. Written informed consent was obtained from all patients
before inclusion.
The patients were initially treated with RVD induction comprising three
21-day cycles of lenalidomide 25mg on days 1− 14, bortezomib 1.3 mg/m2
on days 1, 4, 8, 11 subcutaneously and dexamethasone 20mg/day on days
1− 2, 4− 5, 8− 9 and 11− 12. The mobilization in arm A was CY 2 g/m2 on
day +1 plus ﬁlgrastim 5 μg/kg starting on day +4 and in arm B ﬁlgrastim
10 μg/kg alone starting on day +1. The apheresis was scheduled to begin if
the blood CD34+ cell level was 410× 106/L on day +10 or on day +5
in arms A and B, respectively. The second apheresis was started if the yield
of the ﬁrst apheresis was not ⩾ 3× 106/kg for one or ⩾ 6 × 106/kg for
double graft. Plerixafor was started at 10−11 PM hours with a dose of
240 μg/kg, if blood CD34+ level was o10× 106/L in both arms provided
that WBC count was ⩾ 10 × 109/L in arm A or day +5 had been achieved in
arm B. Plerixafor was also scheduled if the yield of the ﬁrst apheresis was
o1× 106/kg CD34+ cells. If plerixafor was started on these criteria, it was
continued until the predetermined CD34+ cell number (⩾ 3 ×106/kg for
a single transplant, ⩾ 6 × 106/kg for patients with an option for two
transplants) was achieved.
The stem cell aphereses were centralized in the collection units at ﬁve
university hospitals in Finland. Of all procedures, 90% were performed
using the Spectra Optia MNC Program (Spectra Optia Apheresis System,
Software 7.2, Terumo BCT Lakewood, CO, USA) processing 2.3− 3 times
total blood volume. The remaining 10% of the collections were performed
using Fresenius COM.TEC (Blood Cell Separator Fresenius Hemo Care
GmbH, Bad Homburg, Germany). All ﬁve ﬂow cytometry laboratories
participate in CD34+ Stem Cell Enumeration trials organized by UK NEQAS
(www.ukneqasli.co.uk) six times a year with concordant results. The
number of grafts to be collected for each patient was determined in
advance in each study center. After collection, the patients received a
single ASCT after melphalan 200mg/m2. The use of G-CSF was
recommended after the graft infusion on day +5 onwards if the number of
CD34+ cells collected was o3× 106/kg.
Study end points
The primary end point of the mobilization study was the proportion of
patients with a yield ⩾ 3× 106/kg for one transplant with 1− 2 aphereses.
Secondary end points were the number of aphereses needed to reach a
yield ⩾ 3× 106/kg (⩾6 × 106/kg for double graft), the need for plerixafor
use and the proportion of patients reaching ⩾ 2× 106/kg CD34+ cells
(minimum collection target) with ⩽ 3 aphereses. This study was approved
by the Finnish Medicines Agency and registered at www.clinicaltrials.gov
as #NCT01790737.
Statistics
This was a phase II study where the immunophenotypic remission rate
during protocol treatment was considered as the primary end point for
sample size calculation (n= 80) for the entire study. With regard to this
mobilization substudy, we hypothesized that 90% of patients in arm A
would achieve the deﬁned goal without plerixafor compared with 60% of
patients in arm B. With this hypothesis, the sample size of 32 patients per
arm would be needed to show statistically signiﬁcant difference between
arms CY+G-CSF compared with G-CSF alone mobilization with 80% power
and with 5% alpha error. Analyses were performed in all patients and
between the two mobilization groups. All calculations and statistical
analyses were conducted using the appropriate software (IBM SPSS
Statistics 22.Ink, Chicago, IL, USA). Comparisons between the two study
arms regarding continuous variables were performed using Mann–Whitney
U-test and variation inside the groups was described in ranges. Fisher's
exact test was used to compare the categorical variables between the
study arms. Continuous variables were presented in medians with ranges
and categorical variables in percentages. All P-values were two-tailed and
values o0.05 were considered statistically signiﬁcant.
RESULTS
Mobilization of CD34+ cells
From January 2013 to February 2015, altogether 80 MM patients
were included and randomized. By 18th of May 2015, 69 patients,
34 in arm A and 35 in arm B, were mobilized and harvested. Eleven
patients (14%) were dropped out early before mobilization and
collection due to toxicity (n= 9) or early progression (n= 2)
(Supplementary Information, Consortium Flowchart). The patient
characteristics are presented in Table 1. Blood CD34+ cell counts
on the ﬁrst apheresis day were similar between the arms, with
medians of 43 (12− 258) × 106/L and 39 (12− 149) × 106/L,
respectively (P= 0.719; Table 2). A statistical difference emerged
in the median number of blood CD34+ cells before the second
collection, 45 (9− 140) × 106/L and 33 (18− 95) × 106/L, (P= 0.032;
Figure 1). The median of the blood CD34+ cell peak was 67
(14− 258) × 106/L and 44 (18–149) × 106/L (P= 0.106) and this was
achieved on day +11 (10–15) and +5 (4–7) in arms A and B,
respectively.
Collection of CD34+ cells
There was no statistical difference between arms A and B with
regard to the primary study end point, that is, the proportion of
patients achieving a yield of at least ⩾ 3× 106/kg with 1− 2
aphereses (94 and 77%, respectively, P= 0.084; Table 2). Arm A was
superior regarding one of the secondary end points namely the
number of aphereses needed to reach yield ⩾ 3× 106/kg, 1 vs 2,
P= 0.035. The double graft goal (⩾6× 106/kg) was predetermined
Table 1. Baseline patient demographic and clinical characteristics







62 (48− 69) 63 (40− 70) 0.995
Gender, M/F, n (%) 18/16 (53/47) 19/16 (54/46) 0.551
Paraprotein isotype, n (%) 0.606
IgG 22 (65) 22 (63)
IgA 6 (18) 9 (26)
Light chain 6 (17) 4 (11)
ISS, n (%) 0.438
I 6 (17) 13 (37)
II 23 (68) 15 (43)
III 5 (15) 7 (20)
Hemoglobin, g/L,
median (range)
104 (64− 141) 103 (75− 139) 0.810
P-creatinine, μmol/L,
median (range)
82 (53− 158) 80 (47− 404) 0.442
S-β2-microglobulin,
mg/L, median (range)
3.5 (1.1− 12.8) 3.0 (1.6− 16.6) 0.890
Bone marrow plasma
cells, % (range)
48 (13− 95) 50 (7− 100) 0.906
IMWG risk 0.160
Low risk 5 (15) 3 (8)
Standard risk 26 (76) 25 (72)
High risk 3 (9) 7 (20)
Abbreviations: CY= cyclophosphamide; F= female; IgG= immunoglobulin G;
IgA= immunoglobulin A; IMWG= International Myeloma Working Group;
ISS= international staging system; M=male.
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for 21/34 (62%) and 18/35 (51%) of patients in arms A and B,
respectively (P= 0.469). The proportion of patients able
to achieve this goal with 1− 2 aphereses was 62% in arm A and
50% in arm B (P= 0.662). All patients in both arms reached
the secondary end point, a yield of ⩾ 2× 106/kg CD34+ cells
(minimum collection target) with ⩽ 3 aphereses. The total number
of CD34+ cells collected was higher after CY 2 g/m2+G-CSF
than after G-CSF alone, with medians of 6.7 (2.2− 12.4) × 106/kg
and 5.3 (2.4− 12.4) × 106/kg, respectively (P= 0.012). Plerixafor
was needed for 2 (6%) patients in arm A and for 5 (14%) patients
in arm B (P= 0.428).
There was a statistically signiﬁcant difference between the arms
regarding the yield of the ﬁrst apheresis after CY+G-CSF (median
4.0 (0.8− 12.4) × 106/kg) and after G-CSF (2.7 (0.5− 12.4) × 106/kg)
(P= 0.023; Table 2). The median CD34+ cell yields in both arms per
apheresis are shown in Figure 2. There was no difference between
total blood volume processed between study arms (P= 0.841).
There was no statistically signiﬁcant difference with respect to the
yield ⩾ 4 × 106/kg (target for a single transplant suggested by
International Myeloma Working Group19) with one apheresis;
17/34 (50%) achieved it in arm A compared with 10/35 (29%) in
arm B, P= 0.057. Days of hospitalization as well as toxicity during
mobilization and apheresis are shown in Table 3.
Transplantation and engraftment
There was a statistical difference between the arms regarding the
number of CD34+ cells infused after high-dose melphalan 4.3
(2.2− 7.3) × 106/kg and 3.2 (2.3− 6.2) × 106/kg in arms A and B,
respectively (P= 0.010). The engraftment kinetics were, however,
similar regarding the recovery of neutrophil counts 40.5 × 109/L
(days +14 (9− 28) and +14 (11− 27), P= 0.879) and platelet counts
420× 109/L without platelet infusions (days +12 (8− 30) and 11
(8− 30), P= 0.672) and blood counts on day +15 (except the
lymphocyte count difference, 0.5 × 109/L (0.1− 2.8) and 0.7 × 109/L
(0.2− 2.6), P= 0.019) in arms A and B, respectively. Use of G-CSF
after graft infusion was equal in both arms (43% and 40% in arms
A and B, respectively, P= 1.000). The median recovery of
neutrophils appeared on day +12 (11− 19) in patients with
CD34+ cells infused o3 × 109/L who had G-CSF support by the
protocol and on day +14 (9− 28) in patients with CD34+ cell count
⩾ 3 × 109/L without G-CSF support after ASCT. There was no
difference between the arms in hospitalization days during ASCT
(Table 3). No early deaths owing to infections or any other causes
were observed in transplanted patients with at least short-term
follow-up. There were fewer patients with neutropenic fever
during ASCT in the G-CSF arm. There was no difference in the
need for supportive care during ASCT according to the
mobilization arms.
DISCUSSION
ASCT remains the standard up-front treatment for MM patients at
least until the results of two large randomized prospective
multicenter trials comparing ASCT with novel agents and early
Table 2. Mobilization and harvesting results
Arm A (CY+G-CSF), N= 34 Arm B (G-CSF), N=35 P
Blood CD34+ cells × 106/L at ﬁrst apheresis, median (range) 43 (12− 258) 39 (12− 149) 0.719
CD34+ cell yield × 106/kg with ﬁrst apheresis, median range 4.0 (0.8− 12.4) 2.7 (0.5− 12.4) 0.023
Peak blood CD34+ cells × 106/L, median (range) 67 (14− 258) 44 (18− 149) 0.106
Plerixafor use, N (%) 2 (6) 5 (14) 0.428
Primary end point yield ⩾ 3× 106/kg with 1− 2 harvests, N (%) 32/34 (94) 27/35 (77) 0.084
Primary end point yield ⩾ 6× 106/kg for double graft with 1− 2 harvests, N (%) 13/21 (62) 9/18 (50) 0.662
Median no. of aphereses
⩾ 3 ×106/kg, median (range) 1 (1− 3) 2 (1− 3) 0.035
⩾ 6 ×106/kg, median (range) 2 (1− 3) 3 (1− 4) 0.241
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Figure 1. Median and range of blood CD34+ cells (×106/L) before


































Figure 2. Median and range of CD34+ stem cell yields of apheresis
on days 1− 3.
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vs delayed ASCT have been published.25–26 On the other hand,
debate continues regarding a double graft option for MM patients
aged o65− 70 years. After VAD induction, very few patients
failed to mobilize an adequate number of CD34+ cells for double
transplantation.27 In the era of novel agents, some concern has
been raised regarding the adequacy of the stem cell yields after
lenalidomide-based induction. Our randomized study showed that
although CY-based mobilization was more effective G-CSF alone
was successful in a great majority of patients to reach the deﬁned
collection target after a short course of lenalidomide-based
induction.
The mechanisms behind the mobilization problems after
lenalidomide have been investigated by the groups of Koh
et al.28 and Pal et al.,29 who found a maturation arrest of
neutrophils causing the upregulation of intrinsic G-CSF. Based on
that, patients could develop tachyphylaxis for the use of G-CSF
and ﬁnally end in failure in the harvest phase. Lenalidomide seems
to induce localization of C-X-C chemokine receptor 4 (CXCR4) in
the cell surface and increase the binding of CXCR4 to stromal-
derived factor-1α, which blocks the mobilization of CD34+ cells
and could be overcome using plerixafor.30 In contrast to
lenalidomide, bortezomib has been demonstrated to have some
enhancing effects with CY+ﬁlgrastim mobilization,31–32 and a pilot
study on ﬁlgrastim plus bortezomib mobilization has been
registered.33 In our previous study34 of bortezomib-based (VD)
induction followed by low-dose CY 2 g/m2+G-CSF mobilization,
the yields were about 30% higher (9.9 × 106/kg (2.9− 14.6) with a
median of two aphereses) than in this study, suggesting some
detrimental effects even of a short course of lenalidomide in terms
of CD34+ cell mobilization.
In the present study, the median CD34+ cell yields after CY+G-
CSF mobilization were comparable with those in other studies
using RVD as induction.14–15 There are no data for comparison
with regard to RVD induction followed by mobilization with G-CSF
alone. The highest blood CD34+ cell counts in our CY+G-CSF arm
were slightly lower than those seen after VAD induction followed
by CY+G-CSF mobilization, even if the response to induction is
better with the novel induction treatments.6 The lower blood
CD34+ cell counts after lenalidomide exposure can usually be
successfully compensated by the use of plerixafor.18
In our randomized mobilization study, we observed that the
percentage of patients reaching the primary end point was similar
after CY+G-CSF compared with G-CSF alone mobilization regimen,
and all patients achieved the minimum collection target at ﬁrst
attempt. Because in our study the accepted goal for one graft
was ⩾ 3 × 106/kg instead of the usual recommendation of
⩾ 4 × 106/kg,19,21 we analyzed whether there would have been a
difference in toxicity during ASCT between the patient groups
having received CD34+ cells o4 or ⩾ 4 × 106/kg after MEL200.
There was no statistically signiﬁcant difference in terms of
neutropenic fever, number of red cell or platelet transfusions,
neutrophil or platelet engraftment or hospitalization during ASCT.
In the CY arm, CD34+ cell yields were higher after the ﬁrst and the
second harvests even if blood CD34+ levels were higher only
before second harvest. On the other hand, patients in CY+G-CSF
arm had three extra hospital days compared with G-CSF alone arm
based on long distances to the hospitals in Finland.
In conclusion, low-dose CY+G-CSF is more effective than G-CSF
alone in autologous stem cell mobilization in MM patients in terms
of the number of aphereses needed and graft CD34+ content.
However, G-CSF alone mobilization could be an alternative after
induction with three cycles of RVD to harvest even for a double
transplant program. Plerixafor was needed for 6% of the patients
after CY+G-CSF and for 14% of patients in the G-CSF arm. In all of
these patients, the graft could be successfully collected without
need for a second mobilization attempt. Based on these results
with limited number of patients, CY 2 g/m2 might be omitted in
mobilization in MM patients, at least after three-cycle RVD
induction. However, if the goal were ⩾ 4 × 106/kg19,21 for one
graft and the number of grafts to be collected were two for a
younger myeloma patient the best regimen at this moment may
still be CY+G-CSF+/− plerixafor up-front.
Our next step will be a comparison of the graft cellular
compositions and immune reconstitution after high-dose therapy
between these mobilization arms as well as costs associated with
the mobilization and collection phases between the arms. These
aspects will be of importance with regard to optimizing
mobilization strategies in myeloma patients scheduled for ASCT.
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Table 3. Hospitalization, toxicity and need for supportive care during mobilization and ASCT in myeloma patients according to the mobilization arm
Arm A (CY+G-CSF), N=34 Arm B (G-CSF), N= 35 P
Days in hospital during mobilization, median (range) 3 (1− 5) 0 (0− 2) o0.001
Days in hospital during apheresis, median (range) 3 (1− 11) 3 (1− 5) 0.228
Fever during mobilization, N (%) 4 (12%) 1 (3%) 0.169
IV antibiotics during mobilization, days median (range) 0 (0− 9) 0 (0− 12) 0.800
Toxic deaths during mobilization 0 0
Neutropenic fever during ASCT, N (%) 28 (90) 18 (67) 0.049
Platelet infusions during ASCT, units (range) 4 (0− 24) 8 (0− 28) 0.516
Red cell infusions during ASCT, units, (range) 0 (0–6) 0 (0− 10) 0.567
Toxic deaths during ASCT 0 0
Days in hospital during ASCT, median (range) 21 (14− 72), N= 31 19 (14− 29), N= 27 0.577
Abbreviations: ASCT= autologous stem cell transplantation; CY= cyclophosphamide.
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